Skip to main content
Clinical Trials/NL-OMON40379
NL-OMON40379
Completed
Phase 3

A Randomized Controlled Multicenter Study of an Incisionless Operating Platform for Primary Obesity vs. Diet-Exercise alone: The MILEPOST Study - MILEPOST

SGI Medical, Inc0 sites20 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Obesity
Sponsor
SGI Medical, Inc
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
SGI Medical, Inc

Eligibility Criteria

Inclusion Criteria

  • \* Age 20\-60 years
  • \* BMI of \>30 and \<40 with or without a co\-morbid condition
  • \* Patient has failed more conservative weight reduction alternatives such as supervised diet, exercise or behavior modification programs in the last year
  • \* No significant weight change (\+/\- 5% of total body weight) in last 6 months
  • \* American Society Anesthesiologists\-PS score \* 2 (Appendix III)
  • \* Has not taken any prescription or over the counter weight loss medications for at least 6 months
  • \* Subject agrees not to have any additional weight loss interventional procedures or liposuction for at least 30 months following study enrollment,
  • \* Subject is willing to cooperate with post\-operative dietary recommendations and assessment tests
  • \* Signed informed consent

Exclusion Criteria

  • \* History of (or intra\-operative evidence of) bariatric, gastric or esophageal surgery
  • \* Esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments
  • \* Severe Gastro\-esophageal reflux disease (GERD), defined as symptoms that cause subject severe discomfort, compromise performance of daily activities, and/or condition is not entirely controlled with prescription drug therapy
  • \* Known hiatal hernia \>3cm by history or as determined by UGI exam or endoscopy
  • \* Pancreatic insufficiency/disease
  • \* Active peptic ulcer
  • \* Pregnancy or plans of pregnancy in the next 12 months
  • \* Present Corticosteroid Use
  • \* History of inflammatory disease of GI tract; coagulation disorders; hepatic insufficiency or cirrhosis
  • \* History or present use of insulin or insulin derivatives for treatment of diabetes

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A multicenter, randomized controlled study of the clinical efficacy of intravenous peramivir versus oseltamivir against influenza A and B virus infection in high-risk patientsInfluenza virus infection
JPRN-UMIN000009479agasaki evaluation organization for clinical interventions120
Active, not recruiting
Phase 1
A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution compared with amorolfine nail lacquer alone for the treatment of dermatophytic onychomycosis (toenail) without matrix involvement - ONICO
EUCTR2009-011125-14-FRPierre Fabre Dermatologie260
Recruiting
Not Applicable
Multicenter randomized controlled study of the influence of lactic peritoneal dialysis fluid on the peritoneum of peritoneal dialysis patients
JPRN-UMIN000022551Tokyo women&#39;s Medical University, Medical Center East40
Recruiting
Phase 1
A multicenter randomized controlled study on the prevention and control of children's pseudomyopia to true myopia
ITMCTR2000004031Ophthalmic Hospital of Chinese Academy of Traditional Chinese Medicine
Active, not recruiting
Not Applicable
A randomised controlled multicentre study for the safety of Depigoid(R)rush scheduleRhinitis and/or rhinoconjunctivitis without uncontrolled asthma caused by clinical relevant sensitisation againts tree pollen, grass pollen or house dust mitesMedDRA version: 8.0Level: LLTClassification code 10001723
EUCTR2005-001584-66-DEETI Pharma GmbH320